May 24, 2012 —Advanced Cardiac Therapeutics Inc., a developer of temperature-sensing cardiac ablation systems, today announced results of several studies related to the company’s Tempasure cardiac ablation catheter. The Tempasure system is designed to improve clinical outcomes with a novel microwave radiometry technology that allows the electrophysiologist to measure the temperature of cardiac tissue during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control. Presentations took place at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

May 24, 2012 — Research led by Christiana Care Health System's Andrew Doorey, M.D., has found that a small number of patients mistakenly undergo bypass surgery after diagnostic angiography.

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that the introduction of multiple, new generic versions of clopidogrel into the U.S. market has led to increased interest in platelet reactivity testing. In addition to increased field interest, Accumetrics reports a 40 percent jump in traffic to its VerifyNow website.

May 23, 2012 — Boston Scientific Corp. announces that the Synergy everolimus-eluting bioabsorbable polymer-coated platinum chromium coronary stent demonstrated noninferior results in treating de novo coronary artery lesions at one year compared to the Promus Element everolimus-eluting platinum chromium stent in the EVOLVE first human use trial. The trial reported one-year clinical and six-month intravascular ultrasound (IVUS) outcomes data, evaluating the safety and effectiveness of the bioabsorbable abluminal polymer-coated Synergy stent.

http://www.bostonscientific.comMay 23, 2012 — Boston Scientific Corp. announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm Promus Element everolimus-eluting platinum chromium (PtCr) stent system in treating de novo coronary lesions in small coronary vessels. Analysis of the data was presented at EuroPCR 2012 in Paris.

May 22, 2012 — New long-term data from the DIVERGE study presented at EuroPCR 2012 showed that the use of the Axxess drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE (major adverse cardiac events) and VLST (very late stent thrombosis) over a four-year period.